Psyence Therapeutics
We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment.
Clinical trials
Psyence is developing clinical trials in the field of palliative care. Our clinical trial program is focused on assessing the safety and efficacy of psilocybin-assisted therapy for the treatment of adjustment disorder in people with terminal diagnoses in comparison to psychotherapy alone. Adjustment disorder is an emotional or behavioural reaction to a stressful event in one’s life. We have partnered with leading psychedelic contract research organisation (CRO) Clerkenwell Health to design and deliver our first clinical trial in the United Kingdom.
Drug development
Psyence is developing pharmaceutical grade psilocybin product for clinical trials. We have entered into an exclusive licensing agreement with Filament Health, a clinical stage natural psychedelic drug development company and will license its proprietary botanical drug candidate PEX010 (25mg), and the associated IP for our UK clinical trial. This drug has received FDA and Health Canada authorisation to enter Phase II and Phase II human clinical trials. In the future we intend to use our own mushrooms for drug development.